The demand for GLP-1 drugs, originally developed to treat type 2 diabetes, has seen a recent surge due to their weight-loss properties.
These new medicines could be a critical milestone in fighting the obesity epidemic, but should employer health plans cover the cost for non-diabetes patients? In this session, OneDigital's Wellbeing and Pharmacy experts share the latest perspectives and considerations for this revolutionary class of medications, considering their potential benefits for diabetic employees and the broader implications for the organization.
Ready to learn more about employer coverage and GLP-1 drugs for weight loss? Download OneDigital's GLP-1 Whitepaper Here.
